Impact BioMedical Inc. Announces Pricing of Initial Public Offering
17 September 2024 - 12:24AM
Impact BioMedical Inc. (NYSE American: IBO), a company discovering
and developing new offerings in human healthcare and wellness today
announced the pricing of its initial public offering of 1,500,000
shares of its common stock at a public offering price of $3.00 per
share. The shares are expected to begin trading on the NYSE
American Market on September 16, 2024, under the ticker symbol
“IBO.”
The offering is expected to close on September 17, 2024, subject
to the satisfaction of customary closing conditions. In addition,
Impact has granted the underwriters a 45-day option to purchase an
additional 225,000 shares of its common stock at the public
offering price, less underwriting discounts, and commissions. All
of the shares of common stock are being offered by Impact
Biomedical. Revere Securities, LLC is the book-running manager for
the offering.
We have agreed to issue to the underwriter warrants to purchase
up to 75,000 shares of our common stock (or 86,250 shares assuming
the over-allotment option is exercised in full), representing five
percent (5%) of the number of shares of our common stock sold in
each offering. The warrants will be exercisable at a price per
share equal to 125% of the initial public offering price per share
at any time and from time to time, in whole or in part, from (9)
months after the commencement of sales in this offering to the
third anniversary thereof.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Impact BioMedical Inc.:Impact BioMedical
Inc. (“IBO”) discovers, confirms, and patents unique science and
technologies resulting in new offerings in human healthcare and
wellness. Once available, IBO works closely with licensing,
co-development, joint ventures, and other relationships to bring
these offerings to market. For more information, visit Impact
Biomedical, Inc. | Reverse Engineering Nature
(impactbiomedinc.com).
Safe Harbor Disclosure:This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date.
Media Contact:Emily
MartinEmail: emartin@impactbiomedinc.com
Investor Relations:info@impactbiomedinc.com
Impact Biomedical (AMEX:IBO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Impact Biomedical (AMEX:IBO)
Historical Stock Chart
From Dec 2023 to Dec 2024